arrow
N

Nathaniel J. Rhodes

midwestern university
H指数:26
被引数:2,390

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of Antiviral Drugs’ Central Nervous System Distribution Using In Vitro Blood–Brain and Blood-CSF Barrier Models: The Impact of Serum Protein Concentration

利用体外血-脑屏障和血-脑脊液屏障模型评估抗病毒药物在中枢神经系统的分布:血清蛋白浓度的影响

2026-10-030
OAAI
Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists

共识指南:急性病患者β-内酰胺类抗生素剂量个体化(由美国临床药学学会、欧洲临床微生物学与传染病学会、欧洲临床微生物学与传染病学会抗感染药物PK/PD研究组、美国传染病学会、国际治疗药物监测与临床毒理学协会、危重病医学会和传染病药师学会联合推荐)

2026-09-300
OAAI
Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO

入住ICU的医院获得性肺炎患者中,接受头孢吡肟治疗且合并与不合并ECMO患者的个体目标药代动力学/药效学达标率。

2025-06-040
OA
In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells

nirmatrelvir渗透到CSF,中枢神经系统细胞,组织和外周血单核细胞中的体外和体内评估

2024-05-100
OAAI